Document is current
Any future updates will be listed below
-
Authors
Nwosu, Zeribe Chike
Song, Mun Gu
di Magliano, Marina Pasca
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Kim, Sung Eun http://orcid.org/0000-0002-4281-5625
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2020R1C1C1013220)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA151588, R01CA198074, R37CA237421, R01CA248160, R01CA244931)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U-M | Comprehensive Cancer Center, University of Michigan (P30CA046592)
- License Information
-
More Information
Article History
Received: 2 August 2022
Revised: 8 January 2023
Accepted: 11 January 2023
First Online: 4 February 2023
Competing interests
: CAL has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics, and T-Knife Therapeutics, and is an inventor on patents pertaining to Kras regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-pathway as a therapeutic approach (US Patent No: 2015126580-A1, 05/07/2015; US Patent No: 20190136238, 05/09/2019; International Patent No: WO2013177426-A2, 04/23/2015). Other authors declare no competing interests.
